| Unit Size | Cost | Quantity | Stock |
|---|
Givinostat is a non-selective histone deacetylase (HDAC) inhibitor. It exhibits antiproliferative and apoptosis inducing activity in urothelial carcinoma cells with distinct HDAC1 and 2 expression profiles. Givinostat also inhibits proliferation and induces apoptosis in some difficult to treat subsets of acute lymphocyctic leukemia (ALL), like those carrying CRLF2 rearrangements. This is possibly due to inhibition of the JAK/STAT pathway.
| Cas No. | 199657-29-9 |
|---|---|
| Purity | ≥98% |
| Formula | C24H27N3O4 • HCl |
| Formula Wt. | 457.96 |
| IUPAC Name | {6-[(Diethylamino)methyl]-2-naphthyl}methyl [4-(hydroxycarbamoyl)phenyl]carbamate |
| Synonym | ITF-2357 Hydrochloride |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Pinkerneil M., Hoffmann M., et al. Inhibition of Class I Histone Deacetylases 1 and 2 Promotes Urothelial Carcinoma Cell Death by Various Mechanisms. Mol Cancer Ther. 15(2):299-312 (2016). PMID: 26772204.
Savino A., Samo J., et al. The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL. Leukemia. 31(11):2365-75 (2017). PMID: 28331226.
